RESUMO
Recent clinical and preclinical studies suggest that selective activators of the M4 muscarinic acetylcholine receptor have potential as a novel treatment for schizophrenia. M4 activation inhibits striatal dopamine release by mobilizing endocannabinoids, providing a mechanism for local effects on dopamine signaling in the striatum but not in extrastriatal areas. G protein-coupled receptors (GPCRs) typically induce endocannabinoid release through activation of Gαq/11-type G proteins whereas M4 transduction occurs through Gαi/o-type G proteins. We now report that the ability of M4 to inhibit dopamine release and induce antipsychotic-like effects in animal models is dependent on co-activation of the Gαq/11-coupled mGlu1 subtype of metabotropic glutamate (mGlu) receptor. This is especially interesting in light of recent findings that multiple loss of function single nucleotide polymorphisms (SNPs) in the human gene encoding mGlu1 (GRM1) are associated with schizophrenia, and points to GRM1/mGlu1 as a gene within the "druggable genome" that could be targeted for the treatment of schizophrenia. Herein, we report that potentiation of mGlu1 signaling following thalamo-striatal stimulation is sufficient to inhibit striatal dopamine release, and that a novel mGlu1 positive allosteric modulator (PAM) exerts robust antipsychotic-like effects through an endocannabinoid-dependent mechanism. However, unlike M4, mGlu1 does not directly inhibit dopamine D1 receptor signaling and does not reduce motivational responding. Taken together, these findings highlight a novel mechanism of cross talk between mGlu1 and M4 and demonstrate that highly selective mGlu1 PAMs may provide a novel strategy for the treatment of positive symptoms associated with schizophrenia.
Assuntos
Regulação Alostérica/efeitos dos fármacos , Antipsicóticos/metabolismo , Receptor Muscarínico M4/metabolismo , Receptores de Glutamato Metabotrópico/metabolismo , Animais , Ácido Glutâmico/metabolismo , Camundongos , Camundongos Endogâmicos C57BLRESUMO
This letter describes the chemical optimization of a new series of M1 positive allosteric modulators (PAMs) based on a novel benzomorpholine core, developed via iterative parallel synthesis, and culminating in the highly utilized rodent in vivo tool compound, VU0486846 (7), devoid of adverse effect liability. This is the first report of the optimization campaign (SAR and DMPK profiling) that led to the discovery of VU0486846 and details all of the challenges faced in allosteric modulator programs (both steep and flat SAR, as well as subtle structural changes affecting CNS penetration and overall physiochemical and DMPK properties).
Assuntos
Descoberta de Drogas , Morfolinas/farmacologia , Pirazóis/farmacologia , Receptor Muscarínico M1/agonistas , Animais , Células CHO , Cricetulus , Humanos , Estrutura Molecular , Morfolinas/síntese química , Morfolinas/química , Pirazóis/síntese química , Pirazóis/química , Ratos , Relação Estrutura-AtividadeRESUMO
This Letter describes the further lead optimization of the VU0486321 series of mGlu1 positive allosteric modulators (PAMs), focused on addressing the recurrent issue of plasma instability of the phthalimide moiety. Here, we evaluated a number of phthalimide bioisosteres, and ultimately identified isoindolinones as the ideal replacement that effectively address plasma instability, while maintaining acceptable mGlu1 PAM potency, DMPK profile, CNS penetration and mGluR selectivity.
Assuntos
Cumarínicos/química , Cumarínicos/farmacologia , Descoberta de Drogas , Furanos/química , Furanos/farmacologia , Isoindóis/química , Isoindóis/farmacologia , Receptores de Glutamato Metabotrópico/metabolismo , Regulação Alostérica/efeitos dos fármacos , Sistema Nervoso Central/efeitos dos fármacos , Sistema Nervoso Central/metabolismo , Relação Dose-Resposta a Droga , Estabilidade de Medicamentos , Humanos , Isoindóis/sangue , Estrutura Molecular , Ftalimidas/sangue , Ftalimidas/química , Ftalimidas/farmacologia , Relação Estrutura-Atividade , Especificidade por SubstratoRESUMO
This letter describes the re-exploration of the mGlu1 PAM Ro 07-11401 scaffold through a multi-dimensional, iterative parallel synthesis approach. Unlike recent series of mGlu1 PAMs with robust SAR, the SAR around the Ro 07-11401 structure was incredibly steep (only â¼6 of 200 analogs displayed mGlu1 PAM activity), and reminiscent of the CPPHA mGlu5 PAM scaffold. Despite the steep SAR, two new thiazole derivatives were discovered with improved in vitro DMPK profiles and â¼3- to 4-fold improvement in CNS exposure (Kps 1.01-1.19); albeit, with a â¼3-fold diminution in mGlu1 PAM potency, yet comparable efficacy (â¼5-fold leftward shift of the glutamate concentration-response curve at 10µM). Thus, this effort has provided additional CNS penetrant mGlu1 PAM tools in a different chemotype than the VU0486321 scaffold. These compounds will permit a better understanding of the pharmacology and therapeutic potential of selective mGlu1 activation, while highlighting the steep SAR challenges that can often be encountered in GPCR allosteric modulator discovery.
Assuntos
Sistema Nervoso Central/efeitos dos fármacos , Antagonistas de Aminoácidos Excitatórios/farmacologia , Receptores de Glutamato Metabotrópico/efeitos dos fármacos , Animais , Sistema Nervoso Central/metabolismo , Descoberta de Drogas , Antagonistas de Aminoácidos Excitatórios/metabolismo , Humanos , Ratos , Relação Estrutura-AtividadeRESUMO
This Letter describes the further lead optimization of the VU0486321 series of mGlu1 positive allosteric modulators (PAMs), driven by recent genetic data linking loss of function GRM1 to schizophrenia. Steep and caveat-laden SAR plagues the series, but ultimately potent mGlu1 PAMs (EC50s â¼5 nM) have resulted with good DMPK properties (low intrinsic clearance, clean CYP profile, modest Fu) and CNS penetration (Kps 0.25-0.97), along with up to >450-fold selectivity versus mGlu4 and mGlu5.
Assuntos
Antipsicóticos/química , Cumarínicos/química , Furanos/química , Compostos Heterocíclicos/química , Receptores de Glutamato Metabotrópico/química , Regulação Alostérica , Animais , Antipsicóticos/farmacocinética , Antipsicóticos/uso terapêutico , Cumarínicos/farmacocinética , Cumarínicos/uso terapêutico , Furanos/farmacocinética , Furanos/uso terapêutico , Meia-Vida , Compostos Heterocíclicos/farmacocinética , Compostos Heterocíclicos/uso terapêutico , Humanos , Ligação Proteica , Ratos , Receptores de Glutamato Metabotrópico/metabolismo , Esquizofrenia/tratamento farmacológico , Relação Estrutura-AtividadeRESUMO
This Letter describes the continued chemical optimization of the VU0453595 series of M1 positive allosteric modulators (PAMs). By surveying alternative 5,6- and 6,6-heterobicylic cores for the 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one core of VU453595, we found new cores that engendered not only comparable or improved M1 PAM potency, but significantly improved CNS distribution (Kps 0.3-3.1). Moreover, this campaign provided fundamentally distinct M1 PAM chemotypes, greatly expanding the available structural diversity for this valuable CNS target, devoid of hydrogen-bond donors.
Assuntos
Fármacos do Sistema Nervoso Central/farmacologia , Sistema Nervoso Central/efeitos dos fármacos , Descoberta de Drogas , Compostos Heterocíclicos/farmacologia , Piridinas/farmacologia , Pirróis/farmacologia , Receptor Muscarínico M1/metabolismo , Regulação Alostérica/efeitos dos fármacos , Animais , Fármacos do Sistema Nervoso Central/síntese química , Fármacos do Sistema Nervoso Central/química , Relação Dose-Resposta a Droga , Compostos Heterocíclicos/síntese química , Compostos Heterocíclicos/química , Estrutura Molecular , Piridinas/síntese química , Piridinas/química , Pirróis/síntese química , Pirróis/química , Ratos , Relação Estrutura-AtividadeRESUMO
This letter describes the further chemical optimization of the picolinamide-derived family of mGlu4 PAMs wherein we identified a 3-amino substituent to the picolinamide warhead that engendered potency, CNS penetration and in vivo efficacy. From this optimization campaign, VU0477886 emerged as a potent (EC50=95nM, 89% Glu Max) mGlu4 PAM with an attractive DMPK profile (brain:plasma Kp=1.3), rat CLp=4.0mL/min/kg, t1/2=3.7h) and robust efficacy in our standard preclinical Parkinson's disease model, haloperidol-induced catalepsy (HIC).
Assuntos
Amidas/farmacologia , Sistema Nervoso Central/efeitos dos fármacos , Descoberta de Drogas , Picolinas/farmacologia , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Regulação Alostérica/efeitos dos fármacos , Amidas/química , Amidas/metabolismo , Animais , Sistema Nervoso Central/metabolismo , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Humanos , Estrutura Molecular , Picolinas/química , Picolinas/metabolismo , Ratos , Relação Estrutura-AtividadeRESUMO
This Letter describes the lead optimization of the VU0486321 series of mGlu1 positive allosteric modulators (PAMs). While first generation PAMs from Roche were reported in the late 1990s, little effort has focused on the development of mGlu1 PAMs since. New genetic data linking loss-of-function mutant mGlu1 receptors to schizophrenia, bipolar disorder and other neuropsychiatric disorders has rekindled interest in the target, but the ideal in vivo probe, for example, with good PK, brain penetration and low plasma protein binding, for robust target validation has been lacking. Here we describe the first modifications to the central aryl core of the VU0486321 series, where robust SAR was noted. Moreover, structural variants were identified that imparted selectivity (up to >793-fold) versus mGlu4.
Assuntos
Cumarínicos/farmacologia , Furanos/farmacologia , Ftalimidas/farmacologia , Receptores de Glutamato Metabotrópico/agonistas , Regulação Alostérica , Animais , Encéfalo/metabolismo , Cumarínicos/sangue , Cumarínicos/síntese química , Cumarínicos/farmacocinética , Furanos/sangue , Furanos/síntese química , Furanos/farmacocinética , Humanos , Microssomos Hepáticos/metabolismo , Ftalimidas/sangue , Ftalimidas/síntese química , Ftalimidas/farmacocinética , Ratos , Receptores de Glutamato Metabotrópico/metabolismo , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
VPS34 has attracted attention in oncology as a target to modulate autophagy. However, the generation of selective VPS34 inhibitors with suitable PK properties has been a difficult task. The discovery of compound 5 provides lessons in hit prioritization and achieving kinase selectivity while maintaining a good in vivo pharmacokinetic profile.
Assuntos
Autofagia , Classe III de Fosfatidilinositol 3-QuinasesRESUMO
Selective activation of the M1 subtype of muscarinic acetylcholine receptor, via positive allosteric modulation (PAM), is an exciting strategy to improve cognition in schizophrenia and Alzheimer's disease patients. However, highly potent M1 ago-PAMs, such as MK-7622, PF-06764427, and PF-06827443, can engender excessive activation of M1, leading to agonist actions in the prefrontal cortex (PFC) that impair cognitive function, induce behavioral convulsions, and result in other classic cholinergic adverse events (AEs). Here, we report a fundamentally new and highly selective M1 PAM, VU0486846. VU0486846 possesses only weak agonist activity in M1-expressing cell lines with high receptor reserve and is devoid of agonist actions in the PFC, unlike previously reported ago-PAMs MK-7622, PF-06764427, and PF-06827443. Moreover, VU0486846 shows no interaction with antagonist binding at the orthosteric acetylcholine (ACh) site (e.g., neither bitopic nor displaying negative cooperativity with [3H]-NMS binding at the orthosteric site), no seizure liability at high brain exposures, and no cholinergic AEs. However, as opposed to ago-PAMs, VU0486846 produces robust efficacy in the novel object recognition model of cognitive function. Importantly, we show for the first time that an M1 PAM can reverse the cognitive deficits induced by atypical antipsychotics, such as risperidone. These findings further strengthen the argument that compounds with modest in vitro M1 PAM activity (EC50 > 100 nM) and pure-PAM activity in native tissues display robust procognitive efficacy without AEs mediated by excessive activation of M1. Overall, the combination of compound assessment with recombinant in vitro assays (mindful of receptor reserve), native tissue systems (PFC), and phenotypic screens (behavioral convulsions) is essential to fully understand and evaluate lead compounds and enhance success in clinical development.
Assuntos
Cognição/efeitos dos fármacos , Condicionamento Psicológico/efeitos dos fármacos , Comportamento Exploratório/efeitos dos fármacos , Morfolinas/farmacologia , Córtex Pré-Frontal/efeitos dos fármacos , Pirazóis/farmacologia , Regulação Alostérica , Animais , Antipsicóticos/toxicidade , Células CHO , Disfunção Cognitiva/induzido quimicamente , Disfunção Cognitiva/fisiopatologia , Cricetulus , Medo , Camundongos , Morfolinas/toxicidade , Pirazóis/toxicidade , Ratos , Risperidona/toxicidade , Convulsões/induzido quimicamenteRESUMO
Both historical clinical and recent preclinical data suggest that the M1 muscarinic acetylcholine receptor is an exciting target for the treatment of Alzheimer's disease and the cognitive and negative symptom clusters in schizophrenia; however, early drug discovery efforts targeting the orthosteric binding site have failed to afford selective M1 activation. Efforts then shifted to focus on selective activation of M1 via either allosteric agonists or positive allosteric modulators (PAMs). While M1 PAMs have robust efficacy in rodent models, some chemotypes can induce cholinergic adverse effects (AEs) that could limit their clinical utility. Here, we report studies aimed at understanding the subtle structural and pharmacological nuances that differentiate efficacy from adverse effect liability within an indole-based series of M1 ago-PAMs. Our data demonstrate that closely related M1 PAMs can display striking differences in their in vivo activities, especially their propensities to induce adverse effects. We report the discovery of a novel PAM in this series that is devoid of observable adverse effect liability. Interestingly, the molecular pharmacology profile of this novel PAM is similar to that of a representative M1 PAM that induces severe AEs. For instance, both compounds are potent ago-PAMs that demonstrate significant interaction with the orthosteric site (either bitopic or negative cooperativity). However, there are subtle differences in efficacies of the compounds at potentiating M1 responses, agonist potencies, and abilities to induce receptor internalization. While these differences may contribute to the differential in vivo profiles of these compounds, the in vitro differences are relatively subtle and highlight the complexities of allosteric modulators and the need to focus on in vivo phenotypic screening to identify safe and effective M1 PAMs.
Assuntos
Regulação Alostérica/efeitos dos fármacos , Descoberta de Drogas , Agonistas Muscarínicos/química , Agonistas Muscarínicos/farmacologia , Receptor Muscarínico M1/efeitos dos fármacos , Animais , Humanos , Camundongos , Agonistas Muscarínicos/síntese química , Ratos , Receptor Muscarínico M1/metabolismo , Relação Estrutura-AtividadeRESUMO
The first total synthesis of Gombamide A (1), a cytotoxic cyclic thiopeptide from the sponge Clathria gombawuiensis, has been achieved. Highlights of the convergent synthesis feature a disulfide bond forming cascade to close the 17-membered macrocycle and a selenoazidylation procedure to access the unusual para-hydroxystyrlyamide (pHSA) moiety. The synthesis required 18 steps, 11 steps in its longest linear sequence, and proceeded in 9.1% overall yield. This work will facilitate the study of the biological effects of Gombamide A and provide groundwork to explore the structure-activity relationship around this rare natural product.
RESUMO
The efficacy of positive allosteric modulators (PAMs) of the metabotropic glutamate receptor 4 (mGlu4) in preclinical rodent models of Parkinson's disease has been established by a number of groups. Here, we report an advanced preclinically characterized mGlu4 PAM, N-(3-chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506). We detail the discovery of VU0418506 starting from a common picolinamide core scaffold and evaluation of a number of amide bioisosteres leading to the novel pyrazolo[4,3-b]pyridine head group. VU0418506 has been characterized as a potent and selective mGlu4 PAM with suitable in vivo pharmacokinetic properties in three preclinical safety species.
Assuntos
Fármacos Atuantes sobre Aminoácidos Excitatórios/síntese química , Fármacos Atuantes sobre Aminoácidos Excitatórios/farmacologia , Ácidos Picolínicos/farmacologia , Pirazóis/síntese química , Piridinas/síntese química , Piridinas/farmacologia , Receptores de Glutamato Metabotrópico/metabolismo , Regulação Alostérica/efeitos dos fármacos , Amidas/química , Amidas/farmacologia , Animais , Cromatografia Líquida de Alta Pressão , Fármacos Atuantes sobre Aminoácidos Excitatórios/química , Humanos , Ácidos Picolínicos/química , Pirazóis/química , Pirazóis/farmacologia , Piridinas/química , Relação Estrutura-AtividadeRESUMO
The therapeutic potential of selective mGlu1 activation is vastly unexplored relative to the other group I mGlu receptor, mGlu5; therefore, our lab has focused considerable effort toward developing mGlu1 positive allosteric modulators (PAMs) suitable as in vivo proof of concept tool compounds. Optimization of a series of mGlu1 PAMs based on an N-(3-chloro-4-(1,3-dioxoisoindolin-2-yl)phenyl)-3-methylfuran-2-carboxamide scaffold provided 17e, a potent (mGlu1 EC50 = 31.8 nM) and highly CNS penetrant (brain to plasma ratio (Kp) of 1.02) mGlu1 PAM tool compound, that potentiated not only wild-type human mGlu1 but also mutant mGlu1 receptors derived from deleterious GRM1 mutations found in schizophrenic patients. Moreover, both electrophysiological and in vivo studies indicate the mGlu1 ago-PAMs/PAMs do not possess the same epileptiform adverse effect liability as mGlu5 ago-PAMs/PAMs and maintain temporal activity suggesting a broader therapeutic window.
Assuntos
Sistema Nervoso Central/metabolismo , Moduladores GABAérgicos/síntese química , Moduladores GABAérgicos/farmacologia , Receptores de Glutamato Metabotrópico/efeitos dos fármacos , Esquizofrenia/genética , Animais , Epilepsia/induzido quimicamente , Agonistas GABAérgicos/efeitos adversos , Agonistas GABAérgicos/farmacocinética , Agonistas GABAérgicos/uso terapêutico , Moduladores GABAérgicos/farmacocinética , Meia-Vida , Humanos , Conformação Molecular , Ratos , Receptor de Glutamato Metabotrópico 5/agonistas , Receptores de Glutamato Metabotrópico/genética , Relação Estrutura-AtividadeRESUMO
Herein, we report the structure-activity relationship of a novel series of (2(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-yl(aryl)methanones as potent, selective, and orally bioavailable metabotropic glutamate receptor subtype 5 (mGlu5) positive allosteric modulators (PAMs). On the basis of its robust in vitro potency and in vivo efficacy in multiple preclinical models of multiple domains of schizophrenia, coupled with a good DMPK profile and an acceptable therapeutic window, 17a (VU0409551/JNJ-46778212) was selected as a candidate for further development.
RESUMO
Schizophrenia is a complex and highly heterogeneous psychiatric disorder whose precise etiology remains elusive. While genome-wide association studies (GWAS) have identified risk genes, they have failed to determine if rare coding single nucleotide polymorphisms (nsSNPs) contribute in schizophrenia. Recently, two independent studies identified 12 rare, deleterious nsSNPS in the GRM1 gene, which encodes the metabotropic glutamate receptor subtype 1 (mGlu1), in schizophrenic patients. Here, we generated stable cell lines expressing the mGlu1 mutant receptors and assessed their pharmacology. Using both the endogenous agonist glutamate and the synthetic agonist DHPG, we found that several of the mutant mGlu1 receptors displayed a loss of function that was not due to a loss in plasma membrane expression. Due to a lack of mGlu1 positive allosteric modulators (PAM) tool compounds active at human mGlu1, we optimized a known mGlu4 PAM/mGlu1 NAM chemotype into a series of potent and selective mGlu1 PAMs by virtue of a double "molecular switch". Employing mGlu1 PAMs from multiple chemotypes, we demonstrate that the mutant receptors can be potentiated by small molecules and in some cases efficacy restored to that comparable to wild type mGlu1 receptors, suggesting deficits in patients with schizophrenia due to these mutations may be amenable to intervention with an mGlu1 PAM. However, in wild type animals, mGlu1 negative allosteric modulators (NAMs) are efficacious in classic models predictive of antipsychotic activity, whereas we show that mGlu1 PAMs have no effect to slight potentiation in these models. These data further highlight the heterogeneity of schizophrenia and the critical role of patient selection strategies in psychiatric clinical trials to match genotype with therapeutic mechanism.
Assuntos
Regulação Alostérica/efeitos dos fármacos , Mutação/genética , Receptores de Glutamato Metabotrópico/química , Receptores de Glutamato Metabotrópico/genética , Esquizofrenia/genética , Bibliotecas de Moléculas Pequenas/farmacologia , Animais , Cálcio/metabolismo , Cromatografia Líquida , Estudo de Associação Genômica Ampla , Ácido Glutâmico/química , Ácido Glutâmico/farmacologia , Células HEK293 , Humanos , Locomoção , Masculino , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo , Estrutura Molecular , Ratos , Ratos Sprague-Dawley , Bibliotecas de Moléculas Pequenas/química , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por MatrizRESUMO
This work deals with the synthesis and evaluation of new compounds designed by combination of 1,4-naphthoquinone and ferrocene fragments in a 3-ferrocenylmethyl-2-hydroxy-1,4-naphthoquinone arrangement. A practical coupling reaction between 2-hydroxy-1,4-naphthoquinone and ferrocenemethanol derivatives has been developed. This procedure can be carried out "on-water", at moderate temperatures and without auxiliaries or catalysts, with moderate to high yields. The synthesized derivatives have shown significant in vitro antiplasmodial activity against chloroquine-sensitive and resistant Plasmodium falciparum strains and it has been shown that this activity is not related to the inhibition of biomineralization of ferriprotoporphyrin IX. Binding energy calculations and docking of these compounds to cytochrome b in comparison with atovaquone have been performed.
Assuntos
Antimaláricos/farmacologia , Compostos Ferrosos/farmacologia , Naftoquinonas/farmacologia , Plasmodium falciparum/efeitos dos fármacos , Antimaláricos/síntese química , Antimaláricos/química , Compostos Ferrosos/química , Metalocenos , Modelos Moleculares , Estrutura Molecular , Naftoquinonas/química , Testes de Sensibilidade ParasitáriaRESUMO
Myeloid cell leukemia 1 (Mcl-1), a member of the Bcl-2 family of proteins, is overexpressed and amplified in various cancers and promotes the aberrant survival of tumor cells that otherwise would undergo apoptosis. Here we describe the discovery of potent and selective Mcl-1 inhibitors using fragment-based methods and structure-based design. NMR-based screening of a large fragment library identified two chemically distinct hit series that bind to different sites on Mcl-1. Members of the two fragment classes were merged together to produce lead compounds that bind to Mcl-1 with a dissociation constant of <100 nM with selectivity for Mcl-1 over Bcl-xL and Bcl-2. Structures of merged compounds when complexed to Mcl-1 were obtained by X-ray crystallography and provide detailed information about the molecular recognition of small-molecule ligands binding Mcl-1. The compounds represent starting points for the discovery of clinically useful Mcl-1 inhibitors for the treatment of a wide variety of cancers.
Assuntos
Antineoplásicos/química , Proteínas Proto-Oncogênicas c-bcl-2/antagonistas & inibidores , Bibliotecas de Moléculas Pequenas/química , Cristalografia por Raios X , Bases de Dados Factuais , Desenho de Fármacos , Humanos , Indóis/síntese química , Indóis/química , Ligantes , Espectroscopia de Ressonância Magnética , Simulação de Acoplamento Molecular , Estrutura Molecular , Proteína de Sequência 1 de Leucemia de Células Mieloides , Ligação Proteica , Proteínas Proto-Oncogênicas c-bcl-2/química , Relação Estrutura-Atividade , Proteína bcl-X/químicaRESUMO
AIM OF THE STUDY: Witheringia solanacea is a small shrub that belongs to the Solanaceae family. The plant is used as an antidiabetic in Costa Rican herbal medicine. The aim of this study was to evaluate the hypoglycemic and antihyperglycemic activity of the aqueous extract of W. solanacea leaves in rodent models. MATERIALS AND METHODS: A crude extract of W. solanacea leaves was prepared in boiling water and the aqueous filtrate was lyophilized. A single oral dose of 250, 500 and 1000 mg/kg of the extract was evaluated for hypoglycemic activity in a glucose tolerance test in normal rats and for antihyperglycemic activity in alloxan-induced (140 mg/kg) diabetic rats. The blood glucose level was determined at different times by the glucose oxidase method. RESULTS: Dosage of 500 and 1000 mg/kg of the extract significantly decreased (p<0.05) blood glucose levels in the glucose tolerance test in normal rats after 1 h, there was no significant difference observed at 250 mg/kg. Dose of 500 mg/kg of the extract significantly reduced (p<0.05) blood glucose levels in alloxan induced hyperglycemic rats at 4 and 5 h. CONCLUSIONS: In the present study, the hypoglycemic and antihyperglycemic potential of the W. solanacea was demonstrated in rats. These results give support to the traditional use of W. solanacea as antidiabetic herbal medicine.